Abiomed Makes Its Case For Impella In High-Risk Angioplasty Cases
This article was originally published in The Gray Sheet
Executive Summary
Abiomed and its PROTECT II trial principal investigator say they are confident that a partial analysis of the halted study presented April 3 will be enough to get Impella-based circulatory support into cardiology guidelines as a recommended tool for high-risk angioplasties.
You may also be interested in...
Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella
The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.
Abiomed’s Impella Cardiac Pump Needs PMA Study, FDA Panel Says
Better data is needed in the form of a PMA study to assess the safety and effectiveness of Abiomed’s flagship Impella 2.5 blood pump, advisory panel recommends.
Abiomed Pipeline Includes Next-Gen Impella, Symphony For Heart Recovery
R&D efforts include higher-powered Impella cVAD and Impella RP for right-side heart failure, Impella Pediatric for kids and Symphony less invasive, partial-assist heart recovery device for class IIIb chronic HF patients.